|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM349093040 |
| 003 |
DE-627 |
| 005 |
20250304031601.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109180
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1163.xml
|
| 035 |
|
|
|a (DE-627)NLM349093040
|
| 035 |
|
|
|a (NLM)36396013
|
| 035 |
|
|
|a (PII)S1521-6616(22)00261-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jahanbani, Shaghayegh
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Increased macrophage phagocytic activity with TLR9 agonist conjugation of an anti- Borrelia burgdorferi monoclonal antibody
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.01.2023
|
| 500 |
|
|
|a Date Revised 12.02.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022. Published by Elsevier Inc.
|
| 520 |
|
|
|a Borrelia burgdorferi (Bb) infection causes Lyme disease, for which there is need for more effective therapies. Here, we sequenced the antibody repertoire of plasmablasts in Bb-infected humans. We expressed recombinant monoclonal antibodies (mAbs) representing the identified plasmablast clonal families, and identified their binding specificities. Our recombinant anti-Bb mAbs exhibit a range of activity in mediating macrophage phagocytosis of Bb. To determine if we could increase the macrophage phagocytosis-promoting activity of our anti-Bb mAbs, we generated a TLR9-agonist CpG-oligo-conjugated anti-BmpA mAb. We demonstrated that our CpG-conjugated anti-BmpA mAb exhibited increased peak Bb phagocytosis at 12-24 h, and sustained macrophage phagocytosis over 60+ hrs. Further, our CpG-conjugated anti-BmpA mAb induced macrophages to exhibit a sustained activation morphology. Our findings demonstrate the potential for TLR9-agonist CpG-oligo conjugates to enhance mAb-mediated clearance of Bb, and this approach might also enhance the activity of other anti-microbial mAbs
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a BmpA
|
| 650 |
|
4 |
|a Borrelia burgdorferi
|
| 650 |
|
4 |
|a Lyme
|
| 650 |
|
4 |
|a Lyme disease
|
| 650 |
|
4 |
|a Macrophage
|
| 650 |
|
4 |
|a Phagocytosis
|
| 650 |
|
4 |
|a TLR9
|
| 650 |
|
7 |
|a Toll-Like Receptor 9
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a TLR9 protein, human
|2 NLM
|
| 700 |
1 |
|
|a Hansen, Paige S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Blum, Lisa K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bastounis, Effie E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ramadoss, Nitya S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pandrala, Mallesh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kirschmann, Jessica Marie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Blacker, Grace Sisemore
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Love, Zelda Z
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Weissman, Irving L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nemati, Fahimeh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tal, Michal Caspi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Robinson, William H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 246(2023) vom: 01. Jan., Seite 109180
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:246
|g year:2023
|g day:01
|g month:01
|g pages:109180
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109180
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 246
|j 2023
|b 01
|c 01
|h 109180
|